



Cardiovascular Ambulatory Care Performance Measures
AMA/PCPI/ACC/AHA-Owned, NQF-Endorsed

P4P Starter Set – ACC Recommendations for MDI Discussion
Level 1 (Core) Measures

Topic	Population Measure	Footnotes
CAD: Antiplatelet Therapy	<p>Percentage of CAD patients who were prescribed antiplatelet therapy^a.</p> <ul style="list-style-type: none"> <i>Numerator</i> – Patients who were prescribed antiplatelet therapy <i>Denominator</i> – All patients with CAD \geq 18 years of age <p>Denominator Exclusion: Documentation of medical reason(s)^b for not prescribing antiplatelet therapy; documentation of patient reason(s)^c for not prescribing antiplatelet therapy.</p>	<p>a. Antiplatelet therapy may include aspirin, clopidogrel, or combination of aspirin and dipyridamole.</p> <p>b. Medical reasons for not prescribing antiplatelet therapy: active bleeding in the previous six months which required hospitalization and/ or transfusion(s), patient on other antiplatelet therapy, etc.</p> <p>c. Patient reasons: economic, social, and/or religious, etc.</p>
CAD: Beta-Blocker Therapy- Prior Myocardial Infarction (MI)	<p>Percentage of CAD patients with prior MI who were prescribed beta-blocker therapy.</p> <ul style="list-style-type: none"> <i>Numerator</i> – Patients who were prescribed beta-blocker therapy <i>Denominator</i> – All patients with CAD \geq 18 years of age with prior MI <p>Denominator Exclusion: Documentation of medical reason(s)^a for not prescribing a beta-blocker; documentation of patient reason(s)^b for not prescribing a beta-blocker.</p>	<p>a. Medical reasons for not prescribing a B-blocker: bradycardia (defined as HR <50 bpm w/o b-blocker therapy), history of Class IV heart failure, history of 2nd or 3rd degree AV block w/o permanent pacemaker, etc.</p> <p>b. Patient reasons: economic, social, and/ or religious, etc.</p>
HF: Left Ventricular Function (LVF) Assessment	<p>Percentage of HF patients with quantitative or qualitative results of LVF assessment recorded.</p> <ul style="list-style-type: none"> <i>Numerator</i> – Patients with quantitative or qualitative results of LVF assessment recorded <i>Denominator</i> – All HF patients \geq 18 years of age 	<p>This measure requires only documentation of a previous LVF assessment anytime previous in the record and that reassessment should be based on a change in clinical status.</p>
HF: Beta-Blocker Therapy	<p>Percentage of HF patients with left ventricular systolic dysfunction (LVSD) who were prescribed beta-blocker therapy</p> <ul style="list-style-type: none"> <i>Numerator</i> – Patients who were prescribed beta-blocker therapy <i>Denominator</i> – All HF patients \geq 18 years of age with LVEF <40% or with moderately or severely depressed LVSF <p>Denominator Exclusion: Documentation of medical reason(s) for not prescribing a beta-blocker; documentation of patient reason(s)^a for not prescribing a beta-blocker.</p>	<p>a. Patient reasons: economic, social, and/or religious, etc.</p>
HF: ACE Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy	<p>Percentage of HF patients with LVSD who were prescribed ACE-I or ARB therapy.</p> <ul style="list-style-type: none"> <i>Numerator</i> – Patients who were prescribed ACE-I or ARB therapy <i>Denominator</i> – All HF patients \geq 18 years of age with LVEF <40% or with moderately or severely depressed LVSF <p>Denominator Exclusion: Documentation of medical reason(s) for not prescribing ACEI or ARB; documentation of patient reason(s)^a for not prescribing ACEI or ARB.</p>	<p>a. Patient reasons: economic, social, and/or religious, etc.</p>

Cardiovascular Ambulatory Care Performance Measures
AMA/PCPI/ACC/AHA-Owned, NQF-Endorsed

P4P Starter Set – ACC Recommendations for MDI Discussion
Level 2 Measures

Topic	Population Measure	Footnotes
CAD: Lipid Profile	Percentage of CAD patients who received at least one lipid profile (or ALL component tests) ^a . <ul style="list-style-type: none"> <i>Numerator</i> – Patients who received at least one lipid profile (or ALL component tests) <i>Denominator</i> – All CAD patients ≥ 18 years of age 	a. Component tests include total cholesterol, HDL-C, LDL-C, and triglycerides.
CAD: Drug Therapy for Lowering LDL-Cholesterol	Percentage of CAD patients who were prescribed lipid-lowering therapy (based on current ACC/AHA guidelines). <ul style="list-style-type: none"> <i>Numerator</i> – Patients who were prescribed lipid-lowering therapy <i>Denominator</i> – All patients with CAD ≥ 18 years of age Denominator Exclusion: Documentation that lipid-lowering therapy was not indicated ^a ; documentation of medical reason(s) ^b for not prescribing lipid-lowering therapy; documentation of patient reason(s) for not prescribing lipid-lowering therapy.	a. Not indicated for lipid-lowering therapy refers to LDL-C <100 b. Medical reasons for not prescribing lipid-lowering therapy: clinical judgment, LDL-C <130, etc c. Patient reasons: economic, social, and/or religious, etc.
CAD: ACE Inhibitor or Angiotensin Receptor (ARB) Therapy	Percentage of CAD patients with diabetes and/or LVSD who were prescribed ACE-I or ARB therapy. <ul style="list-style-type: none"> <i>Numerator</i> – Patients who were prescribed ACE-I or ARB therapy <i>Denominator</i> – All patients with CAD ≥ 18 years of age who also have diabetes and/or LVSD Denominator Inclusion: Patients with CAD who also have diabetes and/or LVSD (LVEF <40% or with moderately or severely depressed LVSF) Denominator Exclusion: Documentation of medical reason(s) ^a for not prescribing ACEI or ARB; documentation of patient reason(s) ^b for not prescribing ACEI or ARB.	a. Medical reasons for not prescribing ACE-I: allergy, angioedema due to ACEI, anuric renal failure due to ACEI, pregnancy, moderate or severe aortic stenosis, etc. b. Patient reasons: economic, social, and/ or religious, etc.
HF: Warfarin Therapy for Patients with Atrial Fibrillation (AF)	Percentage of HF patients with paroxysmal or chronic AF who were prescribed warfarin therapy. <ul style="list-style-type: none"> <i>Numerator</i> – Patients who were prescribed warfarin therapy <i>Denominator</i> – All HF patients ≥ 18 years of age with paroxysmal or chronic AF Denominator Exclusion: Documentation of medical reason(s) for not prescribing warfarin; documentation of patient reason(s) ^a for not prescribing warfarin.	a. Patient reasons: economic, social, and/or religious, etc.

Cardiovascular Ambulatory Care Performance Measures
AMA/PCPI/ACC/AHA-Owned, NQF-Endorsed

P4P Starter Set – ACC Recommendations for MDI Discussion
Level 3 Measures

Topic	Population Measure	Footnotes
CAD: Symptom & Activity Assessment	Percentage of CAD patients who were evaluated for both level of activity and anginal symptoms during one or more office visits. <ul style="list-style-type: none"> • <i>Numerator</i> – Patients evaluated for both level of activity and anginal symptoms during one or more office visits • <i>Denominator</i> – All CAD patients \geq 18 years of age 	
CAD: Smoking Cessation	Percentage of CAD patients who were queried one or more times about cigarette smoking. <ul style="list-style-type: none"> • <i>Numerator</i> – Patients who were queried one or more times about cigarette smoking • <i>Denominator</i> – All CAD patients \geq 18 years of age Percentage of CAD patients identified as cigarette smokers who received smoking cessation intervention. <ul style="list-style-type: none"> • <i>Numerator</i> – Patients who received smoking cessation intervention • <i>Denominator</i> – All CAD patients \geq 18 years of age identified as cigarette smokers. 	
HF: Weight Measurement	Percentage of HF patient visits with weight measurement recorded. <ul style="list-style-type: none"> • <i>Numerator</i> – Patient visits with weight measurement recorded • <i>Denominator</i> – All visits for patients with HF \geq 18 years of age Denominator Exclusion: Patient visits in which physician was unable to weigh patient.	
HF: Assessment of Clinical Symptoms of Volume Overload (Excess)	Percentage of HF patient visits with assessment of clinical <i>symptoms</i> of volume overload (excess) ^a . <ul style="list-style-type: none"> • <i>Numerator</i> – Patient visits with assessment of clinical <i>symptoms</i> of volume overload (excess) • <i>Denominator</i> – All visits for HF patients \geq 18 years of age 	a. Assessment for absence or presence of symptoms of volume overload must include: Dyspnea OR; Orthopnea OR; Documentation of standardized scale or completion of assessment tool
HF: Assessment of Activity Level	Percentage of HF patient visits with assessment of activity level. <ul style="list-style-type: none"> • <i>Numerator</i> – Patients visits with assessment of current level of activity OR documentation of standardized scale or completion of assessment tool • <i>Denominator</i> – All visits for HF patients \geq 18 years of age 	
HTN: Plan of Care	Percentage of patient visits with either SBP \geq 140 mm Hg or DBP \geq 90 mm Hg with documentation of plan of care for hypertension. <ul style="list-style-type: none"> • <i>Numerator</i> – Patients with documented plan of care for hypertension • <i>Denominator</i> – All visits for patients with HTN \geq 18 years of age with either systolic blood pressure \geq 140 mm Hg or diastolic blood pressure \geq90mm Hg 	